Compare Regeneron Pharmaceuticals Inc (REGN) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs United States Natural Gas Fund — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while United States Natural Gas Fund trades at $10.61. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while United States Natural Gas Fund pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| REGN | UNG | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Commodities - Energy |
52-Week High | $812.27 | $16.90 |
52-Week Low | $545.46 | $10.15 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
UNG trades at $10.29, down 2.09% today, with a bearish technical signal driven by moving averages. The ETF tracks natural gas futures, facing volatility from weather and LNG demand shifts. Recent news highlights comparisons with equity-based natural gas ETFs like FCG, emphasizing UNG's direct exposure to Henry Hub spot prices.
Outlook remains tied to natural gas market dynamics, with risks from storage reports and production levels. Investment appeal hinges on commodity price speculation, but high volatility and lack of traditional fundamentals limit suitability for conservative investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
